CB307
Solid Tumors (mCRPC)
Phase 1bActive
Key Facts
About Crescendo Biologics
Crescendo Biologics is a private, clinical-stage biotech leveraging its proprietary Humabody® VH platform to develop next-generation, multi-specific immune cell engagers for cancer. Its lead asset, CB307, is a bispecific in Phase 1b for metastatic castration-resistant prostate cancer (mCRPC), with a second program, CB001/ZL-1102 for psoriasis, in Phase 2 via partner Zai Lab. The company is backed by blue-chip investors and has significant discovery and development collaborations with Takeda, BioNTech, and Zai Lab, validating its platform and providing non-dilutive funding.
View full company profile